Advanced Cell Technology and Curis Show Strong Growth Potential - Blogs - Investor Stemcell Forum
Username or Email Address
Do you already have an account?
Forgot your password?
  • Log in or Sign up

    Welcome to InvestorStemCell
    Be a part of the Future of Medicine and join the InvestorStemCell Community! InvestorStemCell is the world's only community dedicated to Regenerative Medicine. Get started by signing up!
    View RSS Feed


    Advanced Cell Technology and Curis Show Strong Growth Potential

    Rate this Entry
    by , 04-28-2011 at 08:27 AM (25070 Views)
    Advanced Cell Technology and Curis Show Strong Growth Potential
    The Bedford Report Provides Analyst Research on Advanced Cell Technology & Curis

    Companies:Advanced Cell Technology Inc.Curis Inc.
    Related Quotes
    Symbol Price Change
    ACTC.OB 0.18 0.00

    Follow these stocks
    Press Release Source: The Bedford Report On Thursday April 28, 2011, 8:16 am
    NEW YORK, NY--(Marketwire - 04/28/11) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Advanced Cell Technology, Inc. (OTC.BB:ACTC - News) and Curis, Inc. (NASDAQ:CRIS - News). Access to the full company reports can be found at:

    [url=]Advanced Cell Technology | The Bedford Report[/url]

    [url=]Curis | The Bedford Report[/url]

    IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

    The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [url=]The Bedford Report | Analyst Research focused on equities that offer growth opportunities, value, and strong potential return.[/url] and get exclusive access to our numerous analyst reports and industry newsletters.

    Advanced Cell Technologies recently won regulatory approval from a European Medicines Agency's Committee for late-stage human trials of therapies using human embryonic stem cells. Last month Advanced Cell Technology said it ended 2010 with cash and cash equivalents of $15.9 million and less than $1 million of debt, compared to $2.5 million in cash and cash equivalents and $8.4 million of debt in the year-earlier period.

    Curis is a drug development company that is committed to leveraging its "signalling pathway" drug technologies to seek to create new targeted small molecule drug candidates for cancer. Earlier this month shares of Curis surged following a presentation at a cancer conference in Orlando. Investor interest centers on promising data showing that Curis' technology platform may have use in battling a wide variety of different cancers.

    The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [url=]Disclaimer | The Bedford Report[/url]